Formulating Growth: Why Alivus Life Sciences Just Bought a 76% Stake in IQGen-X Pharma

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) officially announced on August 18, 2026, that its Board of Directors has approved a share purchase agreement to acquire a 76% majority stake in IQGen-X Pharma Private Limited. Executed for a cash consideration of approximately 91.2 million rupees (₹9.12 crore), the transaction marks a strategic expansion for the active pharmaceutical ingredient (API) major. The move into advanced formulation development allows Alivus to integrate its core product offerings into downstream delivery formats for highly regulated global markets.

Strategic Pivot into Advanced Formulation Development

The acquisition involves purchasing 8,60,589 equity shares of IQGen-X Pharma, subject to customary contractual adjustments. Founded in October 2016, IQGen-X Pharma specializes in custom research and formulation development across oral solids, sterile injectables, and ophthalmic solutions serving the United States, Europe, Latin America, and other regulated regions.

According to regulatory filings submitted to the National Stock Exchange of India (NSE) and BSE Limited, the transaction will be funded entirely through internal cash accruals. Company leadership noted that while APIs remain the core anchor of the business, the integration creates an end-to-end platform capable of delivering complex therapeutic delivery formats.

Market Positioning and Corporate Impact

For institutional investors and healthcare industry analysts, the transaction represents a calculated step under Nirma Group’s ownership to scale high-margin downstream segments. By combining Alivus's robust API manufacturing network with IQGen-X Pharma's formulation expertise, the consolidated enterprise is positioned to capture expanded wallet share across international generic markets. The strategic fit leverages existing cash reserves without altering debt structures or requiring external capital raising.

Official Sources Section

Transaction valuation figures, equity distribution parameters, and regulatory disclosure details are documented according to corporate statements and exchange filings published by Alivus Life Sciences Limited, BSE Limited, and the National Stock Exchange of India (NSE).

"According to officials, the acquisition enables the company to leverage its core active pharmaceutical ingredients portfolio selectively into advanced formulation development, delivering deep scientific expertise across complex delivery formats."

Why It Matters

The practical implications of this acquisition provide Alivus Life Sciences with an immediate operational foothold in advanced drug formulations. For global healthcare consumers and pharmaceutical partners, the integrated platform streamlines the development pipeline from raw chemical synthesis to finished dose products.

Key Facts at a Glance

• Acquiring Entity: Alivus Life Sciences Limited.

• Target Company: IQGen-X Pharma Private Limited.

• Stake Acquired: 76% majority equity stake (8,60,589 equity shares).

• Deal Consideration: Approximately 91.2 million rupees (₹9.12 crore) in cash.

• Core Focus: Expansion into oral solids, sterile injectables, and ophthalmic formulations.

Frequently Asked Questions (FAQ)

What percentage stake is Alivus Life Sciences acquiring in IQGen-X Pharma?

Alivus is acquiring a 76% majority equity stake in IQGen-X Pharma Private Limited.

What is the total financial consideration for the transaction?

The aggregate cash consideration for the 76% stake is approximately 91.2 million rupees (₹9.12 crore).

What are the core competencies of IQGen-X Pharma?

IQGen-X Pharma specializes in custom research and advanced formulation development for oral solids, sterile injectables, and ophthalmic solutions.

Where are official corporate disclosures for this transaction filed?

Official filings and regulatory updates are published on the portals of BSE Limited and the National Stock Exchange of India (NSE).

Source: Alivus Life Sciences Limited SEBI Filings, BSE Limited, National Stock Exchange of India (NSE)